As previously reported, BofA upgraded Akero Therapeutics (AKRO) to Buy from Neutral with a price target of $63, up from $35. Akero’s 96-week update of its SYMMETRY phase 2b trial of efruxifermin in patients with cirrhosis due to metabolic disease was “impressive” and “transformative,” says the analyst, who notes that shares of Akero and rival FGF21 developer 89bio (ETNB) are up “meaningfully” since Monday. After having hosted a call with a hepatologist key opinion leader, the firm characterizes his impressions as very positive after describing the results as “game-changing,” the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Akero Therapeutics upgraded to Buy from Neutral at BofA
- Biotech Alert: Searches spiking for these stocks today
- Akero Therapeutics 5.333M share Secondary priced at $48.00
- Akero Therapeutics price target raised to $96 from $46 at Morgan Stanley
- Akero Therapeutics price target raised to $73 from $56 at Canaccord
Questions or Comments about the article? Write to editor@tipranks.com